Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

MajesTEC-2 : A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaMultiple Myeloma

Trial Overview Read MoreRead more

This phase I study is trying to understand how safe and tolerable, and determine the optimal dose level, of a targeted therapy (teclistamab) when it is administered in different combinations with other cancer drugs in people with multiple myeloma.
 

This trial is treating patients with multiple myeloma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Commercial Sponsor

Janssen Research & Development, LLC

Summary

This non-randomised, open-label study has six experimental arm all evaluating different treatment regimens. In Experimental Arm A, participants will receive a treatment regimen of Teclistamab + Daratumumab + Pomalidomide. In Experimental Arm B, participants will receive Teclistamab + Daratumumab + Lenalidomide + Bortezomib (21-day Cycles). In Experimental Arm C, participants will receive Teclistamab + Nirogacestat. In Experimental Arm D, participants will receive Teclistamab + Lenalidomide. In Experimental Arm E, participants will receive Teclistamab + Daratumumab + Lenalidomide. In Experimental Arm F, participants will receive Teclistamab + Daratumumab + Lenalidomide + Bortezomib (28-day Cycles).

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Malignant Haematology & Stem Cell Transplantation Service
Prahran
Ms Nola Kennedy
n.kennedy@alfred.org.au
03 9076 2217

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next